Intern Med. 2025 Jul 24. doi: 10.2169/internalmedicine.5829-25. Online ahead of print.
ABSTRACT
We herein report a case of disseminated strongyloidiasis in a 64-year-old man with human T-lymphotropic virus type 1 (HTLV-1) infection who developed the condition after undergoing chemoradiotherapy for lung cancer. Treatment included daily ivermectin, which eradicated Strongyloides stercoralis after 7 days but was interrupted after 14 days due to the development of skin rashes. After excluding ivermectin as the cause of the drug eruption, intermittent ivermectin was continued monthly for six months, with no recurrence of strongyloidiasis or bacteremia. This case highlights the importance of obtaining a comprehensive patient history and making an early diagnosis to improve the outcomes of disseminated strongyloidiasis.
PMID:40707225 | DOI:10.2169/internalmedicine.5829-25
